CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

Core Insights - CERo Therapeutics Holdings, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application 19/019,111, which will provide composition of matter protection for CER-1236 and its use in cancer treatment until 2041 [1][3] - The company has also secured a patent in Japan, increasing its total to 20 granted patents and allowed applications covering CER-1236 and its platform technology internationally [2] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that integrates characteristics of both innate and adaptive immunity [4] - The company’s lead product candidate, CER-1236, is currently undergoing Phase 1 clinical trials for hematological malignancies [4] Intellectual Property and Regulatory Position - The company’s intellectual property portfolio has been strengthened with the recent patent allowances, enhancing its regulatory position and exclusivity in the market [3] - CERo has also received Fast Track and Orphan Drug Designations from the FDA, further solidifying its regulatory advantages [3]